We are live on ! Find out more
KBIO

KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO

Delisted

KBIO was delisted on the 16th of December, 2015.

19 hedge funds and large institutions have $3.36M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

16% less capital invested

Capital invested by funds: $4.01M → $3.36M (-$651K)

21% less funds holding

Funds holding: 2419 (-5)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
5
Reduced
3
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$2.08M -$13.1K -3,088 -0.6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$388K +$50.5K +11,913 +13%
OPPM
3
Opus Point Partners Management
New York
$358K
Renaissance Technologies
4
Renaissance Technologies
New York
$271K +$114K +26,810 +61%
California Public Employees Retirement System
5
California Public Employees Retirement System
California
$42K
OWIM
6
Old West Investment Management
California
$39K +$4.71K +1,112 +12%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$36K
HP
8
Harbourvest Partners
Massachusetts
$28K
GT
9
Glenmede Trust
Pennsylvania
$27K
William Blair & Company
10
William Blair & Company
Illinois
$25K
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$20K
Northern Trust
12
Northern Trust
Illinois
$16K -$3.54K -836 -16%
VWM
13
Valley Wealth Managers
New Jersey
$8K
UBS Group
14
UBS Group
Switzerland
$7K -$16K -3,766 -68%
Goldman Sachs
15
Goldman Sachs
New York
$7K +$509 +120 +7%
Deutsche Bank
16
Deutsche Bank
Germany
$7K +$2.16K +509 +37%
Citigroup
17
Citigroup
New York
$1K +$1.45K +343 New
TRCT
18
Tower Research Capital (TRC)
New York
$1K +$1.62K +382 New
BI
19
BVF Inc
California
-$569K -145,250 Closed
BFA
20
BlackRock Fund Advisors
California
-$64K -16,396 Closed
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
-$31K -7,984 Closed
Millennium Management
22
Millennium Management
New York
-$30K -7,637 Closed
TSS
23
Two Sigma Securities
New York
-$21K -5,367 Closed
BIM
24
BlackRock Investment Management
Delaware
-$3K -638 Closed

KBIO Hedge Fund Activity: Q2 2015 in Review

19 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q2 2015, worth a combined $3.36M — down 16% from $4.01M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of KBIO and 2 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $114K. The largest seller was BVF Inc, exiting entirely with an estimated $569K sold.

  • 19 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q2 2015, down from 24 in Q1 2015.
  • Funds reported $3.36M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q2 2015, down 16% quarter-over-quarter.
  • 2 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q2 2015 and 7 closed out, a net change of -5 holders.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q2 2015 was Renaissance Technologies, an estimated $114K added.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q2 2015 was BVF Inc, an estimated $569K sold.

Based on aggregated 13F filings for Q2 2015.